135 related articles for article (PubMed ID: 27102245)
1. Position statements on genetic test for peritoneal, ovarian, and fallopian tubal cancers: Korean Society of Gynecologic Oncology (KSGO).
Choi MC; Lim MC; Suh DH; Song YJ; Kim TJ; Chang SJ; Kim JW;
J Gynecol Oncol; 2016 Jul; 27(4):e36. PubMed ID: 27102245
[No Abstract] [Full Text] [Related]
2. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation.
Finch A; Beiner M; Lubinski J; Lynch HT; Moller P; Rosen B; Murphy J; Ghadirian P; Friedman E; Foulkes WD; Kim-Sing C; Wagner T; Tung N; Couch F; Stoppa-Lyonnet D; Ainsworth P; Daly M; Pasini B; Gershoni-Baruch R; Eng C; Olopade OI; McLennan J; Karlan B; Weitzel J; Sun P; Narod SA;
JAMA; 2006 Jul; 296(2):185-92. PubMed ID: 16835424
[TBL] [Abstract][Full Text] [Related]
3. Should I Be Tested for BRCA Mutations?
Jin J
JAMA; 2019 Aug; 322(7):702. PubMed ID: 31429898
[No Abstract] [Full Text] [Related]
4. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.
Olivier RI; van Beurden M; Lubsen MA; Rookus MA; Mooij TM; van de Vijver MJ; van't Veer LJ
Br J Cancer; 2004 Apr; 90(8):1492-7. PubMed ID: 15083174
[TBL] [Abstract][Full Text] [Related]
5. The more you look, the more you will find.
Walsh CS
Cancer; 2016 Jan; 122(1):14-6. PubMed ID: 26439222
[No Abstract] [Full Text] [Related]
6. Clinical outcomes of BRCA1/2 pathogenic variants in ovarian cancer cluster region in patients with primary peritoneal, epithelial ovarian, and fallopian tube cancer.
Ha HI; Park EY; Eoh KJ; Lee YJ; Seo SS; Kang S; Park SY; Lim MC
Gynecol Oncol; 2022 Feb; 164(2):415-420. PubMed ID: 34924242
[TBL] [Abstract][Full Text] [Related]
7. Surgical risk-reduction in carriers of BRCA mutations: where do we go from here?
Kauff ND; Barakat RR
Gynecol Oncol; 2004 May; 93(2):277-9. PubMed ID: 15099933
[No Abstract] [Full Text] [Related]
8. Prophylactic salpingo-oophorectomy in a series of 89 women carrying a BRCA1 or a BRCA2 mutation.
Laki F; Kirova YM; This P; Plancher C; Asselain B; Sastre X; Stoppa-Lyonnet D; Salmon R;
Cancer; 2007 May; 109(9):1784-90. PubMed ID: 17351952
[TBL] [Abstract][Full Text] [Related]
9. USPSTF recommends BRCA testing in women based on familial history.
Dangi-Garimella S
Am J Manag Care; 2014 Mar; 20(5 Spec No.):E6. PubMed ID: 25618620
[No Abstract] [Full Text] [Related]
10. BRCA1/2-related ovarian cancers are of tubal origin: a hypothesis.
Piek JM; Verheijen RH; Kenemans P; Massuger LF; Bulten H; van Diest PJ
Gynecol Oncol; 2003 Aug; 90(2):491. PubMed ID: 12893227
[No Abstract] [Full Text] [Related]
11. Outcome of neoadjuvant chemotherapy in BRCA1/2 mutation positive women with advanced-stage Müllerian cancer.
Mahdi H; Gockley A; Esselen K; Marquard J; Nutter B; Yang B; Hinchcliff E; Horowitz N; Rose PG
Gynecol Oncol; 2015 Dec; 139(3):407-12. PubMed ID: 26210778
[TBL] [Abstract][Full Text] [Related]
12. Surgical manual of the Korean Gynecologic Oncology Group: ovarian, tubal, and peritoneal cancers.
Jeon S; Lee SJ; Lim MC; Song T; Bae J; Kim K; Lee JY; Kim SW; Chang SJ; Lee JM
J Gynecol Oncol; 2017 Jan; 28(1):e6. PubMed ID: 27670260
[TBL] [Abstract][Full Text] [Related]
13. Video-assisted genetic counseling in patients with ovarian, fallopian and peritoneal carcinoma.
Watson CH; Ulm M; Blackburn P; Smiley L; Reed M; Covington R; Bokovitz L; Tillmanns T
Gynecol Oncol; 2016 Oct; 143(1):109-112. PubMed ID: 27416795
[TBL] [Abstract][Full Text] [Related]
14. Women harboring BRCA1/2 germline mutations are at risk for breast and female adnexal carcinoma.
Piek JM; Dorsman JC; Zweemer RP; Verheijen RH; van Diest PJ; Colgan TJ
Int J Gynecol Pathol; 2003 Jul; 22(3):315-6; author reply 315-6. PubMed ID: 12819403
[No Abstract] [Full Text] [Related]
15. Summaries for patients. Assessing the genetic risk for BRCA-related breast or ovarian cancer in women: recommendations from the U.S. Preventive Services Task Force.
Ann Intern Med; 2014 Feb; 160(4):I-16. PubMed ID: 25006622
[No Abstract] [Full Text] [Related]
16. Outcome of preventive surgery and screening for breast and ovarian cancer in BRCA mutation carriers.
Scheuer L; Kauff N; Robson M; Kelly B; Barakat R; Satagopan J; Ellis N; Hensley M; Boyd J; Borgen P; Norton L; Offit K
J Clin Oncol; 2002 Mar; 20(5):1260-8. PubMed ID: 11870168
[TBL] [Abstract][Full Text] [Related]
17. Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective.
Piek JM; Verheijen RH; van Diest PJ
Histopathology; 2009 Mar; 54(4):494-5. PubMed ID: 19309405
[No Abstract] [Full Text] [Related]
18. Society of Gynecologic Oncologists Clinical Practice Committee Statement on Prophylactic Salpingo-oophorectomy.
Gynecol Oncol; 2005 Aug; 98(2):179-81. PubMed ID: 15979696
[No Abstract] [Full Text] [Related]
19. USPSTF Recommendations for BRCA1 and BRCA2 Testing in the Context of a Transformative National Cancer Control Plan.
Rajagopal PS; Nielsen S; Olopade OI
JAMA Netw Open; 2019 Aug; 2(8):e1910142. PubMed ID: 31434110
[No Abstract] [Full Text] [Related]
20. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
Kauff ND; Satagopan JM; Robson ME; Scheuer L; Hensley M; Hudis CA; Ellis NA; Boyd J; Borgen PI; Barakat RR; Norton L; Castiel M; Nafa K; Offit K
N Engl J Med; 2002 May; 346(21):1609-15. PubMed ID: 12023992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
